Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 9/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL772488 | 0.94 | NR1I2 (0.40) | NR1I2PRKCAMMP12CYP3A4CYP2C9 | |
| SCHEMBL771380 | 0.94 | NR1I2 (0.40) | NR1I2PRKCAMMP12CYP3A4CYP2C9 | |
| SCHEMBL775190 | 0.92 | ESR1 (0.40) | NR1I2PRKCAMMP12CYP3A4CYP2C9 | |
| SCHEMBL2202854 | 0.92 | NR1I2 (0.39) | NR1I2PRKCAMMP12CYP3A4CYP2C9 | |
| SCHEMBL2202880 | 0.91 | CYP3A4 (0.41) | NR1I2PRKCAMMP12CYP3A4CYP2C9 | |
| SCHEMBL774602 | 0.91 | NR1I2 (0.38) | NR1I2PRKCAMMP12CYP3A4CYP2C9 | |
| SCHEMBL771847 | 0.91 | CYP3A4 (0.40) | NR1I2PRKCAMMP12CYP3A4CYP2C9 | |
| SCHEMBL772418 | 0.91 | NR1I2 (0.38) | NR1I2PRKCAMMP12CYP3A4CYP2C9 | |
| SCHEMBL772415 | 0.91 | NR1I2 (0.41) | NR1I2PRKCAMMP12CYP3A4CYP2C9 | |
| SCHEMBL773807 | 0.90 | PRKCA (0.48) | NR1I2PRKCAMMP12CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | NR1I2 1189/4885PRKCA 2404/4885MMP12 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.